

New trial to evaluate an investigational drug for Parkinson's disease

26 August 2019 | News

SEP361-203 study evaluating an investigational medication in people with Parkinson's disease experiencing Hallucinations and Delusions



Suncoast Neuroscience Associates is recruiting for a clinical research study to evaluate an investigational medication in people diagnosed with Parkinson's disease who are experiencing symptoms such as seeing things/hearing things that may not actually be there. The study results will provide information about the safety of the investigational medication and how well it works. Patients who choose to take part in clinical research studies provide a valuable contribution to medical research.

The study has been authorized to be conducted at Suncoast Neuroscience Associates by the IRB on March 22, 2019.

Recruitment and patient care will be led by Dr Alberto Vasquez and his team until Fall 2019.

Parkinson's disease is a neurodegenerative condition. This means that patients with Parkinson's disease, have their brain change over time causing problems like losing control of how their body moves. They may also experience other symptoms such as visual hallucinations (seeing things that aren't actually there), delusions (such as paranoia), or illusions (thinking something is real when it is not). These symptoms are often referred to as 'Parkinson's disease psychosis', which is common in people with Parkinson's disease.

About the SEP361-203 study: The SEP361-203 study is evaluating an investigational medication for people with Parkinson's disease that may be experiencing visual hallucinations and/or delusions. Approximately 36 people across 20 clinical research sites in the U.S. will take part in the study. The study will evaluate how safe the investigational medication is and how well it works.